Volume 20 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(10): 1666-1671
HE Hua, LIU Shao-peng, LIU Hai-chao, BAI Ming-hui. The mechanism and clinical significance of SPARCL1 down-regulation expression on gemcitabine resistance in gallbladder cancer[J]. Chinese Journal of General Practice, 2022, 20(10): 1666-1671. doi: 10.16766/j.cnki.issn.1674-4152.002674
Citation: HE Hua, LIU Shao-peng, LIU Hai-chao, BAI Ming-hui. The mechanism and clinical significance of SPARCL1 down-regulation expression on gemcitabine resistance in gallbladder cancer[J]. Chinese Journal of General Practice, 2022, 20(10): 1666-1671. doi: 10.16766/j.cnki.issn.1674-4152.002674
shu

The mechanism and clinical significance of SPARCL1 down-regulation expression on gemcitabine resistance in gallbladder cancer

doi: 10.16766/j.cnki.issn.1674-4152.002674

  • Department of Hepatobiliary and Pancreatic Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan 471000, China

Funds:

 LHGJ20191194

 1820003A

  • Received Date: 2021-05-15
    Available Online: 2022-11-30
    Abstract
  •   Objective   To examine the role of cysteine rich acidic secretory glycoprotein analogue 1 (SPARCL1) in gallbladder cancer.   Methods   Gemcitabine resistant human gallbladder carcinoma cell line GBC-SD/GEM cell line was divided into blank control and SPARCL1 overexpression transfection groups. The expression levels of SPARCL1, matrix metalloproteinase-9 (MMP-9), vimentin (VIM) and fibronectin 1 (FN1), and the proliferation ability of each cell was detected after transfection. The expression of SPARCL1 in 50 cases of gallbladder cancer (gemcitabine-resistant group and-sensitive group) and paracancerous tissues operated in Luoyang Central Hospital from January 2014 to January 2017 were detected, and its relationship with the clinicopathologic features and prognoses of patients were analysed.   Results   The expression of SPARCL1 gene (29.12±1.10) and SPARCL1 protein (23.08±2.15) in the transfection group were significantly higher than that in the control group respectively (3.34±0.98, 2.58±0.71, all P < 0.05). The proliferation capacities and expression levels of MMP-9, VIM and FN1 in the SPARCL1 transfection group were 33.09±12.11, 1.69±0.75, 1.78±0.43 and 1.62±0.31, which were all significantly lower than those in the control group (327.15±9.28, 3.81±0.78, 4.12±0.24, 4.69±0.63, all P < 0.05). The expression of SPARCL1 in gemcitabine resistance group, sensitive group and paracancerous tissues were 5.65±2.01, 15.02±1.17 and 28.46±2.53, respectively, the difference between groups was significant (P < 0.05). SPARCL1 expression was independent of gender, age, pathological type, tumour size, CA19-9, CEA and tumour stage (all P > 0.05), but significantly correlated with lymph node metastasis and tumour differentiation (all P < 0.05). Median survival time of patients in the gemcitabine-resistant group was significantly lower than that of the sensitive group (14.77 months vs. 27.28 months).   Conclusion   SPARCL1 is poorly expressed in gallbladder cancer and is associated with gemcitabine chemotherapy resistance and prognosis.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    李福利, 夏咸军, 刘洪, 等. 高尔基磷酸化蛋白3在胆囊癌组织中表达的临床意义及其与血管生成的关系[J]. 中国普通外科杂志, 2020, 29(2): 190-197. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202002014.htm

    LI F L, XIA X J, LIU H, et al. Clinical significance of expression of Golgi phosphorylation protein 3 in gallbladder carcinoma tissue and its association with angiogenesis[J]. Chinese Journal of General Surgery, 2020, 29(2): 190-197. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202002014.htm
    [2]
    章娴, 陈一兴, 孙菁, 等. 胆囊癌根治术后复发因素分析及放疗靶区指导[J]. 中国临床医学, 2020, 27(3): 380-385. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202003010.htm

    ZANG X, CHEN Y X, SUN J, et al. Prognostic factors of locoregional failure of gallbladder cancer after radical resection: guidance for adjuvant radiotherapy[J]. Chinese Journal Of Clinical Medicine, 2020, 27(3): 380-385. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202003010.htm
    [3]
    SHEN C Y, YIN Y, CHEN H J, et al. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors[J]. BMC Gastroenterol, 2018, 18(1): 105. doi: 10.1186/s12876-018-0833-8
    [4]
    WANG H Y, FENG C, LU M X, et al. Integrative single-cell transcriptome analysis reveals a subpopulation of fibroblasts associated with favorable prognosis of liver cancer patients[J]. Transl Oncol, 2021, 14(1): 100981. DOI: 10.1016/j.tranon.2020.100981.
    [5]
    EVILORIA K, MUNASINGHE A, ASHER S, et al. A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth[J]. Sci Rep, 2016, 25(6): 37839. DOI: 10.1038/srep37839.
    [6]
    KLINGLER A, REGENSBURGER D, TENKERIAN C, et al. Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues[J]. PLoS One, 2020, 21: 15(5): e0233422. DOI: 10.1371/journal.pone.0233422.
    [7]
    蔡香雪, 李婷, 韦露薇, 等. 抑癌基因SPARCL1低表达对卵巢癌耐药和临床预后的影响[J]. 现代妇产科进展, 2020, 29(4): 256-262. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202004006.htm

    CAI X X, LI T, WEI L W, et al. Low expression of SPARCL1 contribute to cisplatin resistance and predict poor prognosis in ovarian cancer[J]. Progress in Obstetrics and Gynecology, 2020, 29(4): 256-262. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202004006.htm
    [8]
    施骅, 潘俊娣, 叶斌. 替吉奥联合卡培他滨对胆囊癌患者炎性因子和淋巴细胞功能的影响[J]. 中华全科医学, 2017, 15(6): 954-956. doi: 10.16766/j.cnki.issn.1674-4152.2017.06.013

    SHI H, PAN J D, YE B. The influence of tegafur combined with capecitabine on inflammatory factors and lymphocyte function of patients with gallbladder cancer[J]. Chinese Journal of General Practice, 2017, 15(6): 954-956. doi: 10.16766/j.cnki.issn.1674-4152.2017.06.013
    [9]
    GONG K, GONG Z J, LU P X, et al. PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma[J]. Biochem Biophys Res Commun, 2019, 27, 516(3): 983-990.
    [10]
    张淦梅. 肿瘤病理诊断中特殊染色联合免疫组化技术的应用效果及检测阳性率评价[J]. 临床检验杂志(电子版), 2019, 8(4): 262-263. https://www.cnki.com.cn/Article/CJFDTOTAL-LNJI201904221.htm

    ZHANG G M. Application effect and positive rate evaluation of special staining combined with immunohistochemistry in tumor pathological diagnosis[J]. Clinical Laboratory Journal(Electronic Edition), 2019, 8(4): 262-263. https://www.cnki.com.cn/Article/CJFDTOTAL-LNJI201904221.htm
    [11]
    刘杰, 陈万青, 郑荣寿, 等. 2013年中国胆囊癌发病与死亡分析[J]. 中国肿瘤, 2018, 27(3): 161-166. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201803001.htm

    LIU J, CHEN W Q, ZHENG R S, et al. Incidence and Mortality of Gallbladder Cancer in China, 2013[J]. China Cancer, 2018, 27(3): 161-166. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201803001.htm
    [12]
    焦丹, 柴凤霞, 邢程, 等. 胆囊癌的临床病理特点及淋巴转移的临床病理危险因素分析[J]. 中国普通外科杂志, 2019, 28(8): 983-988. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201908014.htm

    JIAO D, CHAI F X, XING C, et al. Analysis of clinicopathologic characteristics of gallbladder cancer and clinicopathologic risk factors for lymphatic metastasis[J]. Chinese Journal of General Surgery, 2019, 28(8): 983-988. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201908014.htm
    [13]
    YAN S D, WANG Y Y, CHEN X, et al. Clinical analysis of 15 cases of gallbladder neuroendocrine carcinoma and comparison with gallbladder adenocarcinoma using a propensity score matching[J]. Cancer Manag Res, 2020, 26(12): 1437-1446.
    [14]
    WANG Y X, LIU S Y, Yan Y Q, et al. SPARCL1 promotes C2C12 cell differentiation via BMP7-mediated BMP/TGF-β cell signaling pathway[J]. Cell Death Dis, 2019, 10(11): 852.
    [15]
    LIU X J, ZHAO J, LUAN X R, et al. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression[J]. Placenta, 2020(89): 33-41.
    [16]
    王雨欣. SPARCL1调节C2C12细胞分化的机制研究[D]. 哈尔滨: 东北农业大学, 2020.

    WANG Y X. Mechanism of SPARCL1 regulating differentiation of C2C12 cells[D]. Harbin: Northeast Agricultural University, 2020.
    [17]
    LUO H L, CHIANG P H, HUANG C C, et al. Methylation of SPARCL1 is associated with oncologic outcome of advanced upper urinary tract urothelial carcinoma[J]. Int J Mol Sci, 2019, 20(7): 1653.
    [18]
    ZHAO S J, JIANG Y Q, XU N W, et al. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex[J]. Oncogene, 2018, 37(8): 1049-1061.
    [19]
    陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202004020.htm

    CHEN D, QIAN C. Research progress of mesenchymal cell-mediated chemotherapy resistance in tumor microenvironment of breast cancer[J]. Practical Oncology Journal, 2020, 34(4): 382-386. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202004020.htm
    [20]
    李婷. 抑癌基因SPARCL1的表达调控机制及其在卵巢癌顺铂耐药细胞中的功能研究[D]. 南宁: 广西医科大学, 2018.

    LI T. Regulation mechanism of tumor suppressor gene SPARCL1 and its function in cisplatin-resistant ovarian cancer cells[D]. Nanning: Guangxi Medical University, 2018.
    [21]
    钱俊峰, 徐芳, 王洪源, 等. 血清CYFRA21-1、MMP-9及TTF-1水平在诊断肺恶性肿瘤患者中的临床价值[J]. 中华全科医学, 2019, 17(6): 951-954. doi: 10.16766/j.cnki.issn.1674-4152.000833

    QIAN J F, XU F, WANG H Y, et al. Clinical value of CYFRA21-1, MMP-9 and TTF-1 levels in differentiating benign from malignant lung tumors[J]. Chinese Journal of General Practice, 2019, 17(6): 951-954. doi: 10.16766/j.cnki.issn.1674-4152.000833
    [22]
    李静, 刘琴, 柯锦. miR-582-5p通过靶向SOCS1基因调节皮肤黑色素瘤细胞迁移、侵袭和EMT的机制研究[J]. 河北医药, 2021, 43(2): 165-170. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202102001.htm

    LI J, LIU Q, KE J. The effects of miR-582-5p in regulating the migration, invasion and EMT of melanoma cells of skin by targeting SOCS1 gene[J]. Hebei Medical Journal, 2021, 43(2): 165-170. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202102001.htm
    [23]
    AMANDA M, KHALISHA M, FATEMIA M, et al. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer[J]. Cancer Lett, 2020(477): 88-96.
    [24]
    虞阳. SPARCL1在肝门部胆管癌中的表达和作用机制研究[D]. 上海: 第二军医大学, 2017.

    YU Y. Expression and mechanism of SPARCL1 in hilar cholangiocarcinoma[D]. Shanghai: Naval Medical University, 2017.
    [25]
    王进, 余晓凡, 欧阳楠, 等. 甲基化调控SLIT3和SPARCL1基因在吸烟致肺腺癌中的表达及其对患者预后的影响[J]. 中华医学杂志, 2019, 99(20): 1553-1557.

    WANG J, YU X F, OUYANG N, et al. Expression and prognosis effect of methylation-regulated SLIT3 and SPARCL1 genes in smoking-related lung adenocarcinoma[J]. National Medical Journal of China, 2019, 99(20): 1553-1557.
    [26]
    GONG Y B, FAN X H. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1[J]. Eur Rev Med Pharmacol Sci, 2019, 23(6): 2366-2373.
    [27]
    周源. Sparcl1基因在非小细胞肺癌组织中的表达与临床意义及生物学功能[D]. 沈阳: 中国医科大学, 2018.

    ZHOU Y. Expression, clinical significance and biological function of Sparcl1 gene in non-small cell lung cancer[D]. Shenyang: China Medical University, 2018.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (247) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return